Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has reached a significant milestone in the development of its proprietary therapy for multiple sclerosis (MS), reporting the completion of Phase 1 clinical studies and the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for LUCID-MS. The company announced that the Phase 1 studies, conducted in healthy volunteers, demonstrated a favorable safety profile and the therapy was generally well tolerated.
LUCID-MS is a patented therapeutic candidate designed to target demyelination and provide neuroprotection, addressing the underlying neurodegeneration and myelin damage that drive long-term disease progression in MS. The program focuses on the unmet need for therapies capable of directly protecting or restoring myelin integrity, which is critical for maintaining mobility and bodily function. Multiple sclerosis is a chronic autoimmune and neurodegenerative disease where the immune system attacks myelin, the protective sheath around nerve fibers, leading to disrupted nerve communication and a range of debilitating symptoms.
The significance of this development is underscored by the global burden of MS. The disease affects more than 2.8 million people worldwide and approximately 1 million in the USA. Despite the availability of numerous immune-modulating therapies, many patients continue to experience worsening disability. Current treatments often focus on reducing inflammation and relapse frequency but may not adequately address the underlying neurodegeneration and myelin damage that drive long-term disease progression. LUCID-MS aims to fill this gap by directly targeting the myelin repair process.
Quantum BioPharma’s progress with LUCID-MS represents a potential shift in the treatment landscape for MS. If approved, the therapy could offer a new option for patients who have limited choices for halting or reversing the neurological damage caused by the disease. The company’s IND submission to the FDA is a key regulatory step that could pave the way for further clinical trials and eventual market access.
For investors and stakeholders, the advancement of LUCID-MS highlights Quantum BioPharma’s commitment to addressing critical neurological conditions. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
